Wolverine Trading’s Protalix BioTherapeutics PLX Stock Holding History

Wolverine Trading’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$152K	Buy	70,394 +45,886	+187%	+$74.7K	﹤0.01%	5054
2025 Q2	$37.7K	Buy	+24,508	New	+$50.1K	﹤0.01%	4402
2023 Q3	–	Sell	-17,208	Closed	-$37.3K	–	4952
2023 Q2	$37.3K	Buy	+17,208	New	+$41K	﹤0.01%	4009
2021 Q4	–	Sell	-28,168	Closed	-$29.5K	–	6595
2021 Q3	$39K	Sell	28,168 -17,138	-38%	-$26K	﹤0.01%	6058
2021 Q2	$87K	Buy	45,306 +26,508	+141%	+$91.2K	﹤0.01%	5462
2021 Q1	$85K	Buy	18,798 +7,920	+73%	+$36.9K	﹤0.01%	5496
2020 Q4	$38K	Buy	+10,878	New	+$39K	﹤0.01%	4646
2018 Q3	–	Sell	-1,652	Closed	-$8.29K	–	5652
2018 Q2	$9K	Hold	1,652	–	–	﹤0.01%	5041
2018 Q1	$9K	Buy	+1,652	New	+$10.9K	﹤0.01%	5041

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wolverine Trading's PLX Position: Q3 2025 in Review

Wolverine Trading increased its Protalix BioTherapeutics (PLX) stake by 187% in Q3 2025, buying an estimated $74.7K and bringing the position to 70,394 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #5054.

Wolverine Trading first reported a position in PLX in Q1 2018 and has held it in 9 quarters since. 77 funds tracked by Wall St. Rank hold PLX as of Q3 2025.

Wolverine Trading held 70,394 shares of Protalix BioTherapeutics worth $152K as of Q3 2025.
Wolverine Trading bought 45,886 Protalix BioTherapeutics shares in Q3 2025, an estimated $74.7K.
Protalix BioTherapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5054 holding.
Wolverine Trading first reported a position in Protalix BioTherapeutics in Q1 2018 and has held it in 9 quarters since.
77 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.